Firm involved in drug trial fiasco files for bankruptcy
BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7559.114-a (Published 13 July 2006) Cite this as: BMJ 2006;333:114
- Owen Dyer
- London
TeGenero, the German biotechnology firm whose experimental drug TGN1412 caused multiple organ failure in six men during a clinical trial in England, has filed for bankruptcy.
“The unforeseeable adverse reactions caused by TGN1412 in the TGN1412-HV phase I trial have made it impossible to attract the investment necessary for the company to continue operations,” the company said in a statement. “In view of the fact that there appears [to be] no reasonable prospect that the company can continue its business, TeGenero's management had no alternative but to commence insolvency proceedings.”
The Bavarian company, founded in 2000 by scientists from Würzburg University, will be administered by an official receiver as …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.